Watson Completes Acquisition of Eden Biodesign

Eden Biodesign, a globally-integrated provider of biopharmaceutical services and Watson Pharmaceuticals, Inc. (NYSE: WPI – News) today announced the completion of the acquisition of Eden Biopharm Group Limited by Watson for approximately $15 million. As a result of the acquisition of the Arrow Group in December 2009, Watson had previously acquired approximately 36 percent of Eden. Eden, which will be part of Watson Global Brands Division, will maintain its established contract services model, while providing Watson with proven biopharmaceutical development and manufacturing capabilities. [Read the full article]

Hyperdynamics Corporation (NYSE Amex: HDY) today announced that it has finalized the sale of a minority interest in its oil and gas concession offshore the Republic of Guinea (Northwest Africa) to Dana Petroleum plc (LSE: DNX).

Hyperdynamics and Dana signed an Assignment and a Joint Operating Agreement under which the U.K.-based company acquired a 23 percent participating interest in Hyperdynamics’ Production Sharing Contract with the government of the Republic of Guinea (PSC). The assignment and JOA were made under the December 2009 purchase agreement between Hyperdynamics and Dana. According to its terms, Dana is to pay Hyperdynamics approximately $1.7 million for its pro-rata portion of accrued expenses associated with the Hyperdynamics’ ongoing 2-D seismic program and bear a similar share of future costs for the program. [Read the full article]

Acacia Research Corporation (Nasdaq:ACTG – News) announced today that a subsidiary has acquired the rights to patents for information portal software technology.

{loadposition in-article}

“As Acacia’s licensing success grows, more patent owners are selecting us as their partner for the licensing of their patented technologies,” commented Paul Ryan, Acacia Chairman and CEO. “Acacia is rapidly becoming the leader in technology licensing and we continue to grow our base of future revenues by adding new patent portfolios,” concluded Mr. Ryan.

The patented technology generally relates to customizable user interfaces presenting information from a variety of sources and can be used in public, private enterprise, and consumer portals.

Acacia Research subsidiaries develop, acquire, and license patented technologies. [Read the full article]

QuantRx Biomedical Corporation (OTCBB: QTXB) today announced that it has entered into an agreement to acquire NuRx Pharmaceuticals, Inc. (OTCBB: NUXP – News). The transaction is structured as a tax-free, all stock acquisition resulting in a combined company with no debt and a simplified ownership and capital structure. QuantRx expects to benefit from a strengthened competitive and financial position to accelerate efforts to capitalize on opportunities in the growing market for Point-of-Care diagnostic products.

Walter Witoshkin, QuantRx Chairman and Chief Executive Officer, and Sasha Afanassiev, QuantRx Chief Financial Officer, will continue in their respective roles. All Research and Development efforts will continue under the leadership of Dr. William H. Fleming, QuantRx Chief Scientific Officer. [Read the full article]

You may also like...